XT
SGMT icon

XTX Topco’s Sagimet Biosciences SGMT Stock Holding History

XTX Topco’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-38,099
Closed -$199K – 4653
2026
Q1 		$199K Sell
38,099
-53,638
-58% -$299K ﹤0.01% 2846
2025
Q4 		$543K Buy
91,737
+32,003
+54% +$230K 0.01% 1517
2025
Q3 		$410K Buy
59,734
+34,110
+133% +$277K 0.02% 1235
2025
Q2 		$195K Buy
25,624
+14,813
+137% +$62.5K 0.01% 1713
2025
Q1 		$35.2K Buy
+10,811
New +$45.3K ﹤0.01% 2048
2024
Q3 		– Sell
-41,548
Closed -$142K – 2552
2024
Q2 		$142K Sell
41,548
-17,615
-30% -$80.8K 0.01% 1340
2024
Q1 		$321K Buy
59,163
+44,682
+309% +$321K 0.04% 797
2023
Q4 		$78.5K Buy
+14,481
New +$68.3K 0.02% 1156

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

XTX Topco's SGMT Position: Q2 2026 in Review

XTX Topco sold out of Sagimet Biosciences (SGMT) in Q2 2026, closing a stake of 38,099 shares — an estimated $199K sold.

XTX Topco first reported a position in SGMT in Q4 2023 and held it in 8 quarters. The position peaked at $543K in Q4 2025. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • XTX Topco reported no remaining Sagimet Biosciences position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 38,099 Sagimet Biosciences shares in Q2 2026, an estimated $199K.
  • XTX Topco first reported a position in Sagimet Biosciences in Q4 2023 and held it in 8 quarters.
  • XTX Topco's Sagimet Biosciences position peaked at $543K in Q4 2025.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.